(Q37126043)

18 August 2017

1 reference

title

Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction (English)

1 reference

18 August 2017

1 reference

1 reference

Mark Wing

1

1 reference

18 August 2017

publication date

1 January 2008

1 reference

Journal of Immunotoxicology

18 August 2017

published in

1 reference

18 August 2017

volume

5

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

11-15

1 reference

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F15476910801897433

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910801897433

Muromonab CD3. A review of its pharmacology and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910801897433

Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910801897433

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15476910801897433

10.1080/15476910801897433

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference